Lundbeck Inc. (LUN.CO) Release: Vortioxetine Clinical Phase III Data Show Significant Improvement in Symptoms of Major Depression
5/20/2013 10:00:40 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Valby, Denmark, 18 May 2013 - H. Lundbeck A/S (Lundbeck) and partner Takeda Pharmaceutical Company Limited (Takeda) today announced that the companies will be presenting new data on four pivotal studies on vortioxetine, a novel investigational drug under review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of major depression. The phase III data will be presented at the 2013 Annual Meeting of the American Psychiatric Association (APA) in San Francisco, USA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by